Sign Up to like & get
recommendations!
1
Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-203
Abstract: Targeting BCMA with the antibody-drug conjugate GSK2857916 is well tolerated in a phase I trial.
read more here.
Keywords:
targeting bcma;
bcma achieves;
responses multiple;
durable responses ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-071
Abstract: Of 30 patients with relapsed or refractory hairy-cell leukemia, 87% experienced complete responses.
read more here.
Keywords:
responses vemurafenib;
durable responses;
cell leukemia;
hairy cell ... See more keywords